Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Febuxostat

A xanthine oxidase inhibitor, blocking the enzyme that produces uric acid: discovered in Japan, it was approved in the US in 2009 for the long-term treatment of hyperuricaemia in people with gout. This family brings together the active ingredient, metabolites, labelled standards and other impurities.

Did you know?At its US debut it was presented as the first new treatment option in more than 40 years for gout-related hyperuricaemia.

FebuxostatGo to the active ingredient →
FebuxostatActive ingredientFebuxostatCat. No. P-F011-001CAS 144060-53-7
Febuxostat-d7Isotopically labelledFebuxostat-d7Cat. No. P-F011-007CAS 1285539-74-3
Febuxostat-d9Isotopically labelledFebuxostat-d9Cat. No. P-F011-008CAS 1246819-50-0

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.